Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin Effects on Myocardial Fibrosis in Type 2 Diabetes
NCT03782259Phase 4Completed
- Sponsor
- University of Washington
- Start
- Feb 2019
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoints: Extracellular Volume Fraction at 12 months and Global Myocardial Longitudinal Strain at 12 months. Started Feb 2019; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03782259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782259.